检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
机构地区:[1]广西中医学院病理教研室,南宁市530001 [2]广西壮族自治区肿瘤医院,南宁市530021
出 处:《实用医学杂志》2010年第19期3498-3500,共3页The Journal of Practical Medicine
基 金:广西壮族自治区卫生厅重点科研课题(编号:重200313)
摘 要:目的:探讨丝氨酸/苏氨酸激酶15(STK15)在早期乳腺癌组织中的表达及其与人类表皮生长因子受体2(HER2)、雌激素受体(ER)的关系。方法:用免疫组化二步法检测76例有完整随访资料的早期乳腺癌患者乳腺癌组织中STK15、HER2、ER的表达,并进行统计学分析。结果:STK15、HER2、ER在早期乳腺癌组织中的阳性率分别为53.9%、55.3%、43.4%。STK15表达与HER2表达呈正相关(r=0.496,P<0.01),与ER表达呈负相关(r=-0.256,P<0.05)。Kaplan-Meire分析并经Log-Rank检验,显示STK15阴性患者中位生存时间显著高于STK15阳性患者,差异有统计学意义(P<0.05)。单因素分析示STK15、HER2、ER均与预后相关,多因素分析显示只有STK15与预后相关。结论:早期乳腺癌STK15表达与HER2、ER表达有关,STK15阳性表达的早期乳腺癌患者预后差,是早期乳腺癌独立的预后因素,可作为评价早期乳腺癌预后的生物学指标。Objective To explore the expression of STK15 in early breast cancer (EBC) and the relationship of STK15 with HER2 and ER. Methods The expressions of STK15, HER2, and ER in the cancerous tissues were detected by immunohistochemical two-step method in 76 patients and the obtained data were statistically analyzed. Results The positive expression rates of STK15, HER2, and ER were 53.9%, 55.3%, and 43.4%, respectively. STK15 expression was positively related with HER2 (r = 0.496, P 〈 0.01), but negatively related to ER (r = -0.256, P 〈 0.05). Kaplan-Meire survival analysis and Log-Rank test indicated that the median survival time was significantly higher in STK15-negative than in STK15-positive patients. The monovariate analysis showed that these three genes were associated with the prognosis where as the multivariate analysis revealed that STK15 was the only affecting factor for the prognosis. Conclusions STK15 expression in early breast cancer is related with HER2 and ER. The STK15-positive patients have a poor prognosis and STK15 is an independent factor for the prognosis of early breast cancer and may be used as a biological indicator for assessing the prognosis.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:18.117.249.37